Pyxis Oncology, Inc. (PYXS): Form 8-K filed 2026-11-13
- Accepted by EDGAR
- 2026-11-13 16:17 ET
- Event date
- 2026-11-13
- Accession no.
- 0001193125-26-460698
- Original filing
- SEC EDGAR filing index
AI summary of the filing text. It can contain mistakes; the original filing is authoritative.
Pyxis Oncology increases authorized common shares to 380,000,000
Pyxis Oncology stockholders approved increasing authorized common stock from 190,000,000 shares to 380,000,000 shares at the November 13, 2026 special meeting. The charter amendment became effective upon filing in Delaware that day. Stockholders also approved potential adjournments to solicit additional proxies, but none was necessary.
- Authorized common shares increased from 190,000,000 shares to 380,000,000 shares.
- The charter amendment became effective upon filing in Delaware on November 13, 2026.
- The share increase received 78,081,809 votes for, 6,706,849 against and 209,021 abstentions.
- Stockholders approved potential adjournments to solicit additional proxies, but no adjournment was necessary.
shareholder votegovernance
Items reported
- Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
The company amended its articles of incorporation or bylaws without a shareholder vote that was previously disclosed, or changed its fiscal year. - Item 5.07: Submission of Matters to a Vote of Security Holders
The company reports the results of a shareholder meeting: each matter voted on and the votes cast for, against, abstaining and broker non-votes.
Documents
| Type | Description | Document |
|---|---|---|
| 8-K | 8-K | pyxs-20261113.htm |
| EX-3.1 | EX-3.1 | pyxs-ex3_1.htm |
The summary above was generated by AI from the filing text and checked automatically against it. Read the original documents on SEC EDGAR. How to read an 8-K.